<DOC>
	<DOCNO>NCT02738970</DOCNO>
	<brief_summary>This study involve two-part design . Part 1 design determine optimal dose subcutaneous ( SC ) Perjeta , inject alone mixed Herceptin , result comparable exposure intravenous ( IV ) Perjeta . Exposure SC Perjeta IV Perjeta compare use compilation pharmacokinetic ( PK ) parameter area concentration-time curve ( AUC ) , maximum serum concentration ( Cmax ) , time maximum concentration ( Tmax ) , serum trough concentration ( Ctrough ) . Part 2 design confirm dose regimen woman EBC basis safety , tolerability , PK assessment .</brief_summary>
	<brief_title>A Dose-Finding Study Pertuzumab ( Perjeta ) Combination With Trastuzumab ( Herceptin ) Early Breast Cancer ( EBC )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Part 1 : Healthy male volunteer 18 45 year age Part 1 : Left ventricular ejection fraction ( LVEF ) least 55 percent ( % ) Part 1 : Body mass index ( BMI ) 18 32 kilogram per metersquared ( kg/m^2 ) Part 1 : Normal , intact skin without tattoos lesion injection area Part 2 : Females least 18 year age Part 2 : Eastern Cooperative Oncology Group ( ECOG ) performance status 0 Part 2 : Previously treat , nonmetastatic carcinoma breast Part 2 : Baseline LVEF least 55 % Part 2 : Negative pregnancy test use adequate contraceptive measure among woman childbearing potential Part 1 : Positive urine test drug abuse Part 1 : Hepatitis B C , human immunodeficiency virus ( HIV ) Part 1 : Cardiac disease include hypertension hypotension Part 1 : Lower extremity edema Part 1 : Any clinically relevant history systemic disease Part 1 : History breast cancer Part 1 : Chronic corticosteroid use Part 1 : Receipt IV antibiotic within 7 day prior enrollment Part 2 : Concurrent malignancy require therapy may interfere pharmacokinetic investigation , history malignancy within 5 year prior Screening Part 2 : Significant cumulative exposure anthracyclines Part 2 : Serious cardiac disease include uncontrolled hypertension Part 2 : Poor hematologic , renal , hepatic function Part 2 : Pregnant lactate woman Part 2 : Hepatitis B C , HIV Part 2 : Chronic corticosteroid use Part 2 : Receipt IV antibiotic within 7 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>